Cour Pharmaceuticals is focused on developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated diseases. Their core technology involves immune-modifying nanoparticles that aim to treat the root cause of these diseases rather than merely minimizing symptoms. The company's lead product targets celiac disease, and they are also working on treatments for multiple sclerosis (MS) patients.
Cour Pharmaceuticals has made significant strides in the biotechnology sector by advancing nanoparticle technology to reset immune systems. Their innovative approach has the potential to transform treatment paradigms for various immune-mediated conditions. The company has garnered attention for its pioneering work and has established partnerships to further its research and development efforts.
Cour Pharmaceuticals Development - Similar Companies
